

POLISH FINANCIAL SUPERVISION AUTHORITY

Current Report no. 10/2023

Date of preparation: 2023-05-22

Abbreviated name of the Issuer: MABION S.A.

Subject matter: The Company terminates its agreement with Parexel for the clinical trial of MabionCD20

Legal basis: Article 17(1) of MAR - confidential information.

Content of the Report:

With reference to Current Report no. 41/2020 of 29 October 2020 on entering into an agreement with Parexel International IRL Limited with its registered office in Ireland ("Parexel") to conduct a bridging three-arm clinical trial of MabionCD20 "Agreement", the Management Board of Mabion S.A. "Company" hereby informs that on 22 May 2023, it decided to terminate the Agreement.

Such a decision of the Management Board of Mabion S.A. follows the implementation of the Company Strategy for 2023-2027 of whose adoption the Issuer informed in Current Report no. 7/2023 of 18 April 2023. In line with the Company Strategy for 2023-2027, the Company plans to continue its transformation towards a fully integrated CDMO (Contract Development and Manufacturing Organisation) specialising in biologics.

The Agreement is terminated in accordance with its provisions and has no material financial consequences for the Company other than the necessary costs associated with the termination of the clinical trial.

Any further decisions as regards the MabionCD20 bridging clinical trial required for the purposes of the registration of the drug will be at the discretion of a prospective third-party partner who will carry out the registration under a licence granted by the Company and will be responsible for sales and distribution of the product.